|
|
|
|
467
|
Wed, 7/31/2019,
8:30 AM -
10:20 AM
|
CC-113
|
|
Modeling, Design Strategies and Assessment of Biomarkers — Contributed Papers
|
|
Biopharmaceutical Section
|
|
Chair(s): Yodit Seifu, Merck
|
|
8:35 AM
|
Modeling the Prediction Classifier of Overall Survival with Clinical and Gene Expression Data of Leukemia Patients – a Case Study
Kao-Tai Tsai, Celgene
|
|
8:50 AM
|
A New Method for the Analysis of Categorical Data with Repeated Measurements - Demonstrated by Precision Data Analysis for Clinical Diagnostics
Tinghui Yu, AstraZeneca
|
|
9:05 AM
|
Learning Moral Graphs in Construction of High-Dimensional Bayesian Networks for Mixed Data
Bochao Jia, Eli Lilly and Company; Suwa Xu, University of Florida; Faming Liang, Purdue University
|
|
9:20 AM
|
Biomarker Enrichment Subgroup Analysis - a Case Study
Rui Qin, Johnson & Johnson; Steven Sun, J&J; Grace Liu, Johnson & Johnson
|
|
9:35 AM
|
Design Strategies to Assess Benefit for Biomarker Sub-Populations in Phase III Clinical Trials
Bharani Dharan, Novartis Pharmaceuticals; Ekkehard Glimm, Novartis Pharma AG
|
|
9:50 AM
|
Exact Bayesian Screening for Rapidly Identifying Uninformative Features from High-Dimensional Biomedical Arrays
A Lawrence Gould, Merck Research Laboratories; Richard Baumgartner, Merck Research Laboratories
|
|
10:05 AM
|
Prognostic Models from Data Integration of Clinical Characteristics and Gene Expression Data Using Bayesian Networks
Duncan Rotich, University of Kansas Medical Center; Jeffrey A. Thompson, University of Kansas Medical Center
|
